Company
Headquarters: Irvine, CA, United States
CEO: Mr. Cheng-Hsiang Kao
$3.30 Billion
USD as of Jan. 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 17, 2020. VitaSpring Biomedical Co. Ltd. Was incorporated in 2016 and is headquartered in Irvine, California.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Oct. 31, 2022 |
| Revenue TTM | $5.0 M |
| EBITDA | $1.5 M |
| Gross Profit TTM | $2.0 M |
| Profit Margin | 18.79% |
| Operating Margin | 23.62% |
| Quarterly Revenue Growth | % |
VitaSpring Biomedical Co. Ltd has the following listings and related stock indices.
Stock: OTC: VSBC wb_incandescent